Clinical Trial Update: Double-Blinded, Randomized, Placebo-Controlled Study to Investigate the Safety, Tolerability, Pharmacokinetics, and Biochemical Activity of Intravenous Cpn10 Administration in Subjects With Mild to Moderate SLE. [Phase 1, Phase 2]

View source ↗

Summary

Phase 1/2 trial evaluating intravenous Cpn10 in mild-to-moderate systemic lupus erythematosus; safety, tolerability, pharmacokinetics, and biochemical activity …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Systemic Lupus Erythematosus

Drugs mentioned

• Cpn10

Snippet

Sponsor: Invion, Inc. | Conditions: Lupus Erythematosus, Systemic | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2017-01-30